tiprankstipranks
Trending News
More News >
Telix Pharmaceuticals Ltd. (AU:TLX)
ASX:TLX
Australian Market
Advertisement

Telix Pharmaceuticals (TLX) Share Forecast & Price Target

Compare
398 Followers
See the Price Targets and Ratings of:

TLX Analyst Ratings

Strong Buy
9Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Telix
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TLX Stock 12 Month Forecast

Average Price Target

AU$29.23
▲(54.40% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is AU$29.23 with a high forecast of AU$35.98 and a low forecast of AU$19.49. The average price target represents a 54.40% change from the last price of AU$18.93.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"AU$17","36":"AU$36","21.75":"AU$21.8","26.5":"AU$26.5","31.25":"AU$31.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.97600888076284,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$35.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.2270754583,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$29.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.487004810413204,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$19.49</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,21.75,26.5,31.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.15,21.36738529852022,22.584770597040436,23.802155895560656,25.019541194080873,26.236926492601093,27.454311791121313,28.67169708964153,29.889082388161746,31.106467686681967,32.32385298520219,33.54123828372241,34.75862358224262,{"y":35.97600888076284,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.15,20.848236573715383,21.546473147430767,22.24470972114615,22.94294629486154,23.641182868576923,24.339419442292307,25.03765601600769,25.735892589723075,26.434129163438463,27.132365737153847,27.83060231086923,28.528838884584616,{"y":29.2270754583,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.15,20.099000370031785,20.048000740063568,19.997001110095354,19.946001480127137,19.895001850158923,19.84400222019071,19.793002590222493,19.74200296025428,19.691003330286065,19.64000370031785,19.589004070349635,19.538004440381417,{"y":19.487004810413204,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.97,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetAU$35.98Average Price TargetAU$29.23Lowest Price TargetAU$19.49
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jarden
AU$27.61AU$28.13
Buy
48.60%
Upside
Reiterated
08/22/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Telix Pharmaceuticals (Other OTC: TLPPF) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Morgan Stanley Analyst forecast on AU:TLX
Morgan Stanley
Morgan Stanley
AU$25.6
Buy
35.24%
Upside
Initiated
08/22/25
Promising Growth and Revenue Potential for Telix Pharmaceuticals: Buy Rating Justified
Wilsons
AU$30
Buy
58.48%
Upside
Reiterated
08/22/25
Wilsons Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
Bell Potter Analyst forecast on AU:TLX
Bell Potter
Bell Potter
AU$33AU$30
Buy
58.48%
Upside
Reiterated
08/22/25
Telix Pharmaceuticals (TLPPF) Gets a Buy from Bell Potter
UBS
AU$36
Buy
90.17%
Upside
Reiterated
08/22/25
UBS Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
TR | OpenAI - 4o Analyst forecast on AU:TLX
TR | OpenAI - 4o
TR | OpenAI - 4o
AU$20AU$19.5
Hold
3.01%
Upside
Reiterated
08/22/25
AI Generated ArticleAI Generated Article
TD Cowen
AU$35
Buy
84.89%
Upside
Reiterated
08/20/25
Telix Pharmaceuticals: Strong Revenue Performance and Strategic Positioning Support Buy Rating
Jefferies Analyst forecast on AU:TLX
Jefferies
Jefferies
AU$34AU$32.7
Buy
72.74%
Upside
Reiterated
08/06/25
Jefferies Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
J.P. Morgan Analyst forecast on AU:TLX
J.P. Morgan
J.P. Morgan
AU$31AU$26.25
Buy
38.67%
Upside
Reiterated
08/06/25
J.P. Morgan Remains a Buy on Telix Pharmaceuticals (TLPPF)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jarden
AU$27.61AU$28.13
Buy
48.60%
Upside
Reiterated
08/22/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Telix Pharmaceuticals (Other OTC: TLPPF) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Morgan Stanley Analyst forecast on AU:TLX
Morgan Stanley
Morgan Stanley
AU$25.6
Buy
35.24%
Upside
Initiated
08/22/25
Promising Growth and Revenue Potential for Telix Pharmaceuticals: Buy Rating Justified
Wilsons
AU$30
Buy
58.48%
Upside
Reiterated
08/22/25
Wilsons Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
Bell Potter Analyst forecast on AU:TLX
Bell Potter
Bell Potter
AU$33AU$30
Buy
58.48%
Upside
Reiterated
08/22/25
Telix Pharmaceuticals (TLPPF) Gets a Buy from Bell Potter
UBS
AU$36
Buy
90.17%
Upside
Reiterated
08/22/25
UBS Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
TR | OpenAI - 4o Analyst forecast on AU:TLX
TR | OpenAI - 4o
TR | OpenAI - 4o
AU$20AU$19.5
Hold
3.01%
Upside
Reiterated
08/22/25
AI Generated ArticleAI Generated Article
TD Cowen
AU$35
Buy
84.89%
Upside
Reiterated
08/20/25
Telix Pharmaceuticals: Strong Revenue Performance and Strategic Positioning Support Buy Rating
Jefferies Analyst forecast on AU:TLX
Jefferies
Jefferies
AU$34AU$32.7
Buy
72.74%
Upside
Reiterated
08/06/25
Jefferies Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
J.P. Morgan Analyst forecast on AU:TLX
J.P. Morgan
J.P. Morgan
AU$31AU$26.25
Buy
38.67%
Upside
Reiterated
08/06/25
J.P. Morgan Remains a Buy on Telix Pharmaceuticals (TLPPF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Telix Pharmaceuticals

1 Month
xxx
Success Rate
12/15 ratings generated profit
80%
Average Return
+9.60%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +9.60% per trade.
3 Months
xxx
Success Rate
13/15 ratings generated profit
87%
Average Return
+30.84%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 86.67% of your transactions generating a profit, with an average return of +30.84% per trade.
1 Year
Success Rate
17/20 ratings generated profit
85%
Average Return
+61.72%
reiterated a buy rating 7 days ago
Copying Steven Wheen's trades and holding each position for 1 Year would result in 85.00% of your transactions generating a profit, with an average return of +61.72% per trade.
2 Years
xxx
Success Rate
16/20 ratings generated profit
80%
Average Return
+127.13%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +127.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLX Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
18
15
14
14
22
Buy
2
2
2
0
0
Hold
1
4
4
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
21
20
19
26
In the current month, TLX has received 22 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. TLX average Analyst price target in the past 3 months is 29.23.
Each month's total comprises the sum of three months' worth of ratings.

TLX Financial Forecast

TLX Earnings Forecast

Next quarter’s earnings estimate for TLX is AU$0.23 with a range of -AU$0.07 to AU$0.67. The previous quarter’s EPS was AU$0.02. TLX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year TLX has Preformed in-line its overall industry.
Next quarter’s earnings estimate for TLX is AU$0.23 with a range of -AU$0.07 to AU$0.67. The previous quarter’s EPS was AU$0.02. TLX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year TLX has Preformed in-line its overall industry.

TLX Sales Forecast

Next quarter’s sales forecast for TLX is AU$619.21M with a range of AU$402.00M to AU$680.20M. The previous quarter’s sales results were AU$615.34M. TLX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.91% of the time in the same period. In the last calendar year TLX has Outperformed its overall industry.
Next quarter’s sales forecast for TLX is AU$619.21M with a range of AU$402.00M to AU$680.20M. The previous quarter’s sales results were AU$615.34M. TLX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.91% of the time in the same period. In the last calendar year TLX has Outperformed its overall industry.

TLX Stock Forecast FAQ

What is AU:TLX’s average 12-month price target, according to analysts?
Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 29.23.
    What is AU:TLX’s upside potential, based on the analysts’ average price target?
    Telix Pharmaceuticals Ltd. has 54.40% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Telix Pharmaceuticals Ltd. a Buy, Sell or Hold?
          Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Telix Pharmaceuticals Ltd.’s share price target?
            The average share price target for Telix Pharmaceuticals Ltd. is 29.23. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is AU$35.98 ,and the lowest forecast is AU$19.49. The average share price target represents 54.40% Increase from the current price of AU$18.93.
              What do analysts say about Telix Pharmaceuticals Ltd.?
              Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of Telix Pharmaceuticals Ltd.?
                To buy shares of AU:TLX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis